Download PDF
Thromb Haemost 2010; 103(02): 254-256
DOI: 10.1160/TH09-12-0843
Editorial Focus
Schattauer GmbH

Anticoagulation intensity for elderly atrial fibrillation patients: Should we use a conventional INR target (2.0 to 3.0) or a lower range?

Deirdre A. Lane
1   University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
,
Gregory Y. H. Lip
1   University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
› Author Affiliations
Further Information

Publication History

Received: 16 December 2009

Accepted: 16 January 2009

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-988.
    CrossrefPubMedGoogle Scholar
  • 2 Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 16: 590-592.
    PubMedGoogle Scholar
  • 3 Nieuwlaat R, Capucci A, Lip GY. et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026.
    CrossrefPubMedGoogle Scholar
  • 4 Lane DA, Lip GYH. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008; 39: 7-9.
    CrossrefPubMedGoogle Scholar
  • 5 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomized controlled trial. Lancet 2007; 370: 493-503.
    CrossrefPubMedGoogle Scholar
  • 6 Rash A, Downes T, Portner R. et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007; 36: 151-6.
    CrossrefPubMedGoogle Scholar
  • 7 Tay KH, Lip GY, Lane DA. Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis 2009; 20: 392-393.
    CrossrefPubMedGoogle Scholar
  • 8 Pengo V, Cucchini U, Denas G. et al. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with nonvalvular atrial fibrillation: a randomised primary prevention trial. Thromb Haemost 2009; 103: 442-449.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Hylek EM, Evans-Molina C, Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
    CrossrefPubMedGoogle Scholar
  • 10 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
    CrossrefPubMedGoogle Scholar
  • 11 Hart RG, Halperin JL. Do current guidelines result in overuse of warfarin anticoagulation in patients with atrial fibrillation?. Ann Intern Med 2009; 151: 355-356.
    CrossrefPubMedGoogle Scholar
  • 12 Fuster V, Rydén LE, Cannom DS. et al. ACC/AHA/ ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
    CrossrefPubMedGoogle Scholar
  • 13 Fang MC, Chang Y, Hylek EM. et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752.
    CrossrefPubMedGoogle Scholar
  • 14 Singer DE, Fang MC, Go AS. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med 2009; 169: 2032.
    PubMedGoogle Scholar
  • 15 van Walraven C, Hart RG, Connolly S. et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators. Stroke 2009; 40: 1410-1416.
    CrossrefPubMedGoogle Scholar
  • 16 Rose AJ, Ozonoff A, Henault LE. et al. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008; 6: 1647-1654.
    CrossrefPubMedGoogle Scholar
  • 17 Jones M, McEwan P, Morgan CL. et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477.
    CrossrefPubMedGoogle Scholar
  • 18 Connolly SJ, Pogue J, Eikelboom J. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
    CrossrefPubMedGoogle Scholar
  • 19 Morgan CL, McEwan P, Tukiendorf A. et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37-41.
    CrossrefPubMedGoogle Scholar
  • 20 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
    CrossrefPubMedGoogle Scholar
  • 21 Singer DE, Chang Y, Fang MC. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
    CrossrefPubMedGoogle Scholar